Novabridge Biosciences (NBP) FDA Approvals

Novabridge Biosciences logo
$0.87 +0.05 (+6.04%)
As of 12:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novabridge Biosciences' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Novabridge Biosciences (NBP). Over the past two years, Novabridge Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as VIS-101. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

VIS-101 FDA Regulatory Timeline and Events

VIS-101 is a drug developed by Novabridge Biosciences for the following indication: in patients with wet age-related macular degeneration (wet AMD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Novabridge Biosciences FDA Events - Frequently Asked Questions

As of now, Novabridge Biosciences (NBP) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Novabridge Biosciences (NBP) has reported FDA regulatory activity for VIS-101.

The most recent FDA-related event for Novabridge Biosciences occurred on November 18, 2026, involving VIS-101. The update was categorized as "Dose Update," with the company reporting: "Visara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD")."

Currently, Novabridge Biosciences has one therapy (VIS-101) targeting the following condition: in patients with wet age-related macular degeneration (wet AMD)..

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:NBP last updated on 11/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners